biostudies-literatureSchafer PHCelgeneCancer Research UK1516-1523https://www.ebi.ac.uk/biostudies/studies/S-EPMC6161670biostudies-literatureUnknown77(10)<h4>Objectives</h4><i>IKZF1</i> and <i>IKZF3 (</i>encoding transcription factors Ikaros and Aiolos) are susceptibility loci for systemic lupus erythematosus (SLE). The pharmacology of iberdomide (CC-220), a cereblon (<i>CRBN</i>) modulator targeting Ikaros and Aiolos, was studied in SLE patient cells and in a phase 1 healthy volunteer study.<h4>Methods</h4><i>CRBN</i>, <i>IKZF1</i> and <i>IKZF3</i> gene expression was measured in peripheral blood mononuclear cells (PBMC) from patients with SLE and healthy volunteers. Ikaros and Aiolos protein levels were measured by Western blot and flow cytometry. Anti-dsDNA and anti-phospholipid autoantibodies were measured in SLE PBMC cultures treated for 7 days with iberdomide. Fifty-six healthy volunteers were randomised to a single dose of iberdomideAnnals of the rheumatic diseasesCereblon modulator iberdomide induces degradation of the transcription factors Ikaros and Aiolos: immunomodulation in healthy volunteers and relevance to systemic lupus erythematosus.PMC61616701156622897Schafer PHYang ZWu LThomas MPalmisano MLiu LChopra RRingheim GYe YKosek JfalseCereblon modulator iberdomide induces degradation of the transcription factors Ikaros and Aiolos: immunomodulation in healthy volunteers and relevance to systemic lupus erythematosus.<h4>Objectives</h4><i>IKZF1</i> and <i>IKZF3 (</i>encoding transcription factors Ikaros and Aiolos) are susceptibility loci for systemic lupus erythematosus (SLE). The pharmacology of iberdomide (CC-220), a cereblon (<i>CRBN</i>) modulator targeting Ikaros and Aiolos, was studied in SLE patient cells and in a phase 1 healthy volunteer study.<h4>Methods</h4><i>CRBN</i>, <i>IKZF1</i> and <i>IKZF3</i> gene expression was measured in peripheral blood mononuclear cells (PBMC) from patients with SLE and healthy volunteers. Ikaros and Aiolos protein levels were measured by Western blot and flow cytometry. Anti-dsDNA and anti-phospholipid autoantibodies were measured in SLE PBMC cultures treated for 7 days with iberdomide. Fifty-six healthy volunteers were randomised to a single dose of iberdomide2018-01-01T00:00:00Z2018 Oct2026-06-06T22:41:58.449Z2026-06-06T03:11:16.896ZS-EPMC61616702994592010.1136/annrheumdis-2017-212916